$VKTX I believe NVO wants to know the outcome of maintenance phase of maintenance trial here. If it shows weight loss or stable weight on monthly or biweekly subcutaneous injection that will be spectacular. That will put a lid on LLY’s profit. NVO will definitely jump in to take its market share back and push LLY. The regime will be different with 2735 and will be more cost effective for the patients in longer term.
在 X 查看 ↗